Status:
COMPLETED
A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis
Lead Sponsor:
UCB Pharma
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
This was a multicenter, open-label, randomized, crossover trial in subjects with MS who were already taking a stable dose of baclofen (up to 80 mg/day) for spasticity. The trial was designed to assess...
Eligibility Criteria
Inclusion
- stable dose of baclofen
Exclusion
- not stable dosing
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2005
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00139789
Start Date
January 1 2005
End Date
April 1 2005
Last Update
August 30 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Schwarz
Milwaukee, Wisconsin, United States